These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18451532)

  • 1. Artificial lipids stabilized camptothecin incorporated in liposomes.
    Maitani Y; Katayama S; Kawano K; Hayama A; Toma K
    Biol Pharm Bull; 2008 May; 31(5):990-3. PubMed ID: 18451532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin.
    Watanabe M; Kawano K; Toma K; Hattori Y; Maitani Y
    J Control Release; 2008 May; 127(3):231-8. PubMed ID: 18384903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions.
    Lundberg BB
    Anticancer Drug Des; 1998 Jul; 13(5):453-61. PubMed ID: 9702210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution.
    Flaten GE; Chang TT; Phillips WT; Brandl M; Bao A; Goins B
    J Liposome Res; 2013 Mar; 23(1):70-81. PubMed ID: 23210622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67.
    Joguparthi V; Xiang TX; Anderson BD
    J Pharm Sci; 2008 Jan; 97(1):400-20. PubMed ID: 17879989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of parameters influencing incorporation, retention and cellular cytotoxicity in liposomal formulations of poorly soluble camptothecin.
    Whitaker RD; Ingebrigtsen SG; Naderkhani E; Skar ML; Flaten GE
    J Liposome Res; 2013 Dec; 23(4):298-310. PubMed ID: 23763495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
    Koo OM; Rubinstein I; Onyuksel H
    Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A method to determine the incorporation capacity of camptothecin in liposomes.
    Saetern AM; Flaten GE; Brandl M
    AAPS PharmSciTech; 2004 Jun; 5(3):e40. PubMed ID: 15760073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimeric camptothecin derived phospholipid assembled liposomes with high drug loading for cancer therapy.
    Fang S; Hou Y; Ling L; Wang D; Ismail M; Du Y; Zhang Y; Yao C; Li X
    Colloids Surf B Biointerfaces; 2018 Jun; 166():235-244. PubMed ID: 29604567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Lipid Composition on the Liposomal Delivery of Camptothecin Developed by Active Click Loading.
    Xie L; Zhang Q; Zhu Q; Wang Y; Niu S; Zhang X; Huang Y; Li J; Liu X; Xue Z; Zhao X; Zheng Y
    Mol Pharm; 2024 May; 21(5):2327-2339. PubMed ID: 38576375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and comparative characterization of chitosan, gelatin, and chitosan-gelatin-coated liposomes of CPT-11-HCl.
    Shende P; Gaud R
    Drug Dev Ind Pharm; 2009 May; 35(5):612-8. PubMed ID: 18951273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts.
    Daoud SS; Fetouh MI; Giovanella BC
    Anticancer Drugs; 1995 Feb; 6(1):83-93. PubMed ID: 7756688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redox-sensitive dimeric camptothecin phosphatidylcholines-based liposomes for improved anticancer efficacy.
    He W; Du Y; Zhou W; Yao C; Li X
    Nanomedicine (Lond); 2019 Dec; 14(23):3057-3074. PubMed ID: 31696756
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells.
    Acevedo-Morantes CY; Acevedo-Morantes MT; Suleiman-Rosado D; Ramírez-Vick JE
    Drug Deliv; 2013 Nov; 20(8):338-48. PubMed ID: 24024505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH.
    Joguparthi V; Anderson BD
    J Pharm Sci; 2008 Jan; 97(1):433-54. PubMed ID: 17918731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of hydroxycamptothecin affinities to albumin and membranes by steady-state fluorescence anisotropy measurements.
    Ziomkowska B; Cyrankiewicz M; Kruszewski S
    Comb Chem High Throughput Screen; 2007 Jul; 10(6):486-92. PubMed ID: 17896945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method.
    Stano P; Bufali S; Pisano C; Bucci F; Barbarino M; Santaniello M; Carminati P; Luisi PL
    J Liposome Res; 2004; 14(1-2):87-109. PubMed ID: 15461935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
    Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
    PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-microemulsifying drug delivery system for camptothecin using new bicephalous heterolipid with tertiary-amine as branching element.
    Dhumal DM; Akamanchi KG
    Int J Pharm; 2018 Apr; 541(1-2):48-55. PubMed ID: 29462684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies.
    Sugarman SM; Zou Y; Wasan K; Poirot K; Kumi R; Reddy S; Perez-Soler R
    Cancer Chemother Pharmacol; 1996; 37(6):531-8. PubMed ID: 8612306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.